Lynx1 Capital Management LP Stoke Therapeutics, Inc. Put Options Transaction History
Lynx1 Capital Management LP
- $279 Million
- Q3 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding STOK
# of Institutions
123Shares Held
57.3MCall Options Held
9.3KPut Options Held
35.2K-
Skorpios Trust8.91MShares$124 Million99.85% of portfolio
-
Black Rock Inc. New York, NY5.41MShares$75.2 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.71MShares$65.5 Million3.79% of portfolio
-
Rtw Investments, LP New York, NY4.65MShares$64.7 Million0.91% of portfolio
-
Baker Bros. Advisors LP New York, NY4.37MShares$60.7 Million0.57% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $548M
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...